Funding

Rejuvenate Bio

United States · Biotech

Develops gene therapies for age-related and chronic diseases in animals and humans

Visit rejuvenatebio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Strategic$6MConnecticut Innovations — Role not disclosedDigitalis — Role not disclosedKendall Capital Partners — Role not disclosedMerck Animal Health — Role not disclosedVCapital — Role not disclosed

Investors

Connecticut InnovationsStrategicDigitalisStrategicKendall Capital PartnersStrategicMerck Animal HealthStrategicVCapitalStrategic

Coverage

Jun 8, 2026Rejuvenate Bio · Strategic

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesrejuvenatebio.com ↗